RxDoctor Payments DataLook up a doctor →

Mark Stahl, DO

Allergy & Immunology · San Antonio, TXNPI 1912932476

Payments from drug & device makers

$50,575in general payments, 2019–2025

Across 932 payments — averaging $54.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$21K
  • Regeneron$4K
  • Sanofi$4K
  • AstraZeneca$3K
  • GSK$3K
  • Regeneron Healthcare Solutions, Inc.$3K
  • plus $13K from 33 others

What the payments were for

  • Consulting fees$6,43813%
  • Speaking & faculty fees$19,76539%
  • Travel & lodging$8962%
  • Food & beverage$23,30146%
  • Education$1750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,575 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$471,586
Medicare patients
106
Services billed
16,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab17$70,125
Dupixent SyringeDupilumab14$53,485
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,939
Spiriva RespimatTiotropium Bromide21$15,829
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,827
Breo ElliptaFluticasone/Vilanterol26$10,569
Epinephrine17$3,299
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,286
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,249
Arnuity ElliptaFluticasone Furoate15$3,036
Azelastine-FluticasoneAzelastine/Fluticasone17$2,750
Azelastine Hcl87$2,027
Albuterol Sulfate HfaAlbuterol Sulfate53$1,157
Ipratropium Bromide20$646
Fluticasone Propionate50$567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$3,416$35,54469 claims
Boehringer IngelheimSpiriva Respimat$20,769$15,82921 claims
AstraZenecaBreztri Aerosphere$3,477$10,82718 claims
Hikma Pharmaceuticals USAEpinephrine$62$3,29917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →